Pediatr Blood Cancer. 2006 Jan 19; [Epub ahead of print]
Analysis of biologic surrogate markers from a
Children's Oncology Group Phase I trial of gefitinib in pediatric
patients with solid tumors.
Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM,
Blaney SM, Adamson P, Hidalgo M.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,
Baltimore, Maryland.
This trial evaluated the effect of gefitinib on the plasma circulating
levels of epidermal growth factor receptor (EGFR), vascular endothelial
growth factor (VEGF), matrix metalloproteinases (MMP)-2 and -9 of
patients treated on a pediatric Phase I trial. Complete plasma
correlative studies were obtained from 16 of the 25 enrolled patients.
There was a trend for lower MMP-2 baseline levels in patients with
partial response or stable disease. The Ewing sarcoma from the only
patient with partial response lacked egfr mutations. Gefitinib did not
induce any significant variation in the levels of the assessed
parameters, and none of these determinations showed significant
predictive or prognostic value. Pediatr Blood Cancer (c) 2006
Wiley-Liss, Inc.
PMID: 16425266 [PubMed – as supplied by publisher]